EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases
- PMID: 20136647
- PMCID: PMC3154636
- DOI: 10.1111/j.1468-1331.2010.02951.x
EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases
Abstract
Background and purpose: These European Federation of Neurological Societies guidelines on neuroimaging of motor neuron diseases (MNDs) are designed to provide practical help for the neurologists to make appropriate use of neuroimaging techniques in patients with MNDs, which ranges from diagnostic and monitoring aspects to the in vivo study of the pathobiology of such conditions.
Methods: Literature searches were performed before expert members of the Task Force wrote proposal. Then, consensus was reached by circulating drafts of the manuscript to the Task Force members and by discussion of the classification of evidence and recommendations.
Results and conclusions: The use of conventional MRI in patients suspected of having a MND is yet restricted to exclude other causes of signs and symptoms of MN pathology [class IV, level good clinical practice point (GCPP)]. Although the detection of corticospinal tract hyperintensities on conventional MRI and a T2-hypointense rim in the pre-central gyrus can support a pre-existing suspicion of MND, the specific search of these abnormalities for the purpose of making a firm diagnosis of MND is not recommended (class IV, level GCPP). At present, advanced neuroimaging techniques, including diffusion tensor imaging and proton magnetic resonance spectroscopic imaging, do not have a role in the diagnosis or routine monitoring of MNDs yet (class IV, level GCPP). However, it is strongly advisable to incorporate measures derived from these techniques into new clinical trials as exploratory outcomes to gain additional insights into disease pathophysiology and into the value of these techniques in the (longitudinal) assessment of MNDs (class IV, level GCPP).
Similar articles
-
Thalamic Alterations in Motor Neuron Diseases: A Systematic Review of MRI Findings.J Integr Neurosci. 2024 Apr 10;23(4):77. doi: 10.31083/j.jin2304077. J Integr Neurosci. 2024. PMID: 38682227
-
Role of Magnetic Resonance Imaging in Diagnosis of Motor Neuron Disease: Literature Review and Two Case Illustrations.Perm J. 2019;23:18-131. doi: 10.7812/TPP/18-131. Perm J. 2019. PMID: 30939271 Free PMC article. Review.
-
Neuroimaging of motor neuron diseases.Ther Adv Neurol Disord. 2012 Mar;5(2):119-27. doi: 10.1177/1756285612437562. Ther Adv Neurol Disord. 2012. PMID: 22435076 Free PMC article.
-
Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.Neuroimage Clin. 2019;24:101984. doi: 10.1016/j.nicl.2019.101984. Epub 2019 Aug 16. Neuroimage Clin. 2019. PMID: 31499409 Free PMC article.
-
Analysis of brain and spinal MRI measures in a common domain to investigate directional neurodegeneration in motor neuron disease.J Neurol. 2023 Mar;270(3):1682-1690. doi: 10.1007/s00415-022-11520-1. Epub 2022 Dec 12. J Neurol. 2023. PMID: 36509983 Free PMC article.
Cited by
-
Monitoring Value of Multimodal Magnetic Resonance Imaging in Disease Progression of Amyotrophic Lateral Sclerosis: A Prospective Observational Study.Chin Med J (Engl). 2018 Dec 20;131(24):2904-2909. doi: 10.4103/0366-6999.247214. Chin Med J (Engl). 2018. PMID: 30539901 Free PMC article.
-
Magnetic Resonance Spectroscopy in ALS.Front Neurol. 2019 May 10;10:482. doi: 10.3389/fneur.2019.00482. eCollection 2019. Front Neurol. 2019. PMID: 31133975 Free PMC article. Review.
-
A Systematic Review and Meta-Analysis of the Functional MRI Investigation of Motor Neuron Disease.Front Neurol. 2015 Nov 24;6:246. doi: 10.3389/fneur.2015.00246. eCollection 2015. Front Neurol. 2015. PMID: 26635722 Free PMC article.
-
Multimodal structural MRI in the diagnosis of motor neuron diseases.Neuroimage Clin. 2017 Aug 2;16:240-247. doi: 10.1016/j.nicl.2017.08.002. eCollection 2017. Neuroimage Clin. 2017. PMID: 28794983 Free PMC article.
-
Diagnostic and Prognostic Value of Conventional Brain MRI in the Clinical Work-Up of Patients with Amyotrophic Lateral Sclerosis.J Clin Med. 2020 Aug 6;9(8):2538. doi: 10.3390/jcm9082538. J Clin Med. 2020. PMID: 32781557 Free PMC article.
References
-
- Andersen PM, Borasio GD, Dengler R, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921–938. - PubMed
-
- Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8:94–109. - PubMed
-
- Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994–1003. - PubMed
-
- Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol. 2004;11:577–581. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical